Azitra says press release available on ATR-COSF ex vivo repeat-dose, anti-wrinkle results

AZTR•2026-07-15

Anti-wrinkle study results

A separate ex vivo study showed dose-dependent elasticity gains, up to 4.4-fold, supporting an anti-wrinkle positioning ahead of a planned human study.

ATR-COSF ex vivo repeat-dose results

Azitra said it posted a press release on July 15, 2026, reporting new ex vivo repeat-dose distribution results for its ATR-COSF cosmetic program.

Data showed increased rHDfilaggrin penetration into the stratum granulosum versus prior single-dose work.

Azitra says press release available on ATR-COSF ex vivo repeat-dose, anti-wrinkle results

Anti-wrinkle study results

ATR-COSF ex vivo repeat-dose results

Related News

Amex Halt CPHI.A Add Info Lst 1.180000

Tekedia Capital: China Q2 smartphone shipments fall 4.3% as AI-driven memory costs lift prices

Nasdaq Trade Halt <JTAI.O> Volatility Trading Pause at 11:12 AM

Conagra CEO says he expects to have update on strategic review in early 2027

Sinclair backs FCC move to modernize national TV station ownership cap